US Bancorp DE Buys 118 Shares of Laboratory Co. of America Holdings (NYSE:LH)

US Bancorp DE increased its stake in shares of Laboratory Co. of America Holdings (NYSE:LH) by 0.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 22,421 shares of the medical research company’s stock after acquiring an additional 118 shares during the quarter. US Bancorp DE’s holdings in Laboratory Co. of America were worth $5,142,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. SouthState Corp bought a new position in Laboratory Co. of America during the third quarter worth $28,000. Fortitude Family Office LLC increased its holdings in Laboratory Co. of America by 312.5% in the 4th quarter. Fortitude Family Office LLC now owns 132 shares of the medical research company’s stock valued at $30,000 after buying an additional 100 shares during the period. Geneos Wealth Management Inc. increased its holdings in Laboratory Co. of America by 309.8% in the 4th quarter. Geneos Wealth Management Inc. now owns 168 shares of the medical research company’s stock valued at $39,000 after buying an additional 127 shares during the period. Human Investing LLC bought a new stake in Laboratory Co. of America in the 4th quarter valued at $39,000. Finally, Kennebec Savings Bank bought a new stake in Laboratory Co. of America in the 3rd quarter valued at $42,000. Institutional investors own 95.94% of the company’s stock.

Laboratory Co. of America Stock Down 1.0 %

Shares of NYSE LH opened at $254.31 on Thursday. The firm’s 50-day simple moving average is $242.77 and its 200 day simple moving average is $233.34. The company has a market cap of $21.29 billion, a price-to-earnings ratio of 28.83, a price-to-earnings-growth ratio of 1.71 and a beta of 1.07. The company has a quick ratio of 1.30, a current ratio of 1.44 and a debt-to-equity ratio of 0.67. Laboratory Co. of America Holdings has a 12-month low of $191.97 and a 12-month high of $258.59.

Laboratory Co. of America (NYSE:LH) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $3.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a net margin of 5.73% and a return on equity of 15.29%. On average, research analysts expect that Laboratory Co. of America Holdings will post 16.01 earnings per share for the current fiscal year.

Laboratory Co. of America Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 12th. Investors of record on Thursday, February 27th will be given a dividend of $0.72 per share. The ex-dividend date of this dividend is Thursday, February 27th. This represents a $2.88 annualized dividend and a yield of 1.13%. Laboratory Co. of America’s dividend payout ratio (DPR) is 32.65%.

Wall Street Analysts Forecast Growth

LH has been the topic of several analyst reports. Jefferies Financial Group boosted their price target on shares of Laboratory Co. of America from $275.00 to $290.00 and gave the company a “buy” rating in a report on Thursday, February 6th. Citigroup raised shares of Laboratory Co. of America from a “neutral” rating to a “buy” rating and boosted their price target for the company from $250.00 to $300.00 in a report on Tuesday. UBS Group lowered their price target on shares of Laboratory Co. of America from $293.00 to $286.00 and set a “buy” rating on the stock in a report on Tuesday, January 28th. Morgan Stanley boosted their price target on shares of Laboratory Co. of America from $260.00 to $270.00 and gave the company an “overweight” rating in a report on Tuesday, December 17th. Finally, Barclays lowered their target price on shares of Laboratory Co. of America from $271.00 to $260.00 and set an “equal weight” rating on the stock in a report on Friday, February 7th. Three equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $268.38.

Insider Buying and Selling at Laboratory Co. of America

In other Laboratory Co. of America news, COO Mark S. Schroeder sold 5,339 shares of the company’s stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $249.23, for a total transaction of $1,330,638.97. Following the transaction, the chief operating officer now directly owns 4,960 shares in the company, valued at approximately $1,236,180.80. This represents a 51.84 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Der Vaart Sandra D. Van sold 1,314 shares of the company’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $251.30, for a total transaction of $330,208.20. Following the transaction, the executive vice president now owns 2,171 shares in the company, valued at approximately $545,572.30. The trade was a 37.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 14,000 shares of company stock worth $3,449,757. Company insiders own 0.85% of the company’s stock.

About Laboratory Co. of America

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.